
2023 Another Step Towards Trust: Our MDD Approval
In 2023, we reached a significant milestone that is not only a result of our work but also an expression of our attitude: Inspital's Class I products received approval according to the Medical Device Directive (MDD).
What might appear at first glance as a purely regulatory success means something much deeper to us. Because those who work in medical technology know: approval means responsibility. It means thinking through every process, checking every component, reviewing every procedure with a view to the big picture – the safety and trust of medical professionals and patients worldwide.
This recognition was the result of years of work on our internal quality system, our documentation, and the consistent implementation of our high standards – day after day, product by product. And it was proof that we not only develop what is technically possible, but what is medically and humanly meaningful.
With the MDD approval, new doors opened: to more international partnerships, to expanded markets – and above all, to growing trust in the Inspital brand.
But for us, this step was not an end, but a beginning. Because when it comes to quality, we know no finish line – only constant progress.
2023 was the year in which our quality promise was officially confirmed.
And that commits us – to every further step we take.
News Press
Here you will find current news about trade fairs, congresses, PR and other relevant topics.